Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label attachment file name title previous answer version answering member constituency answering member printed answering member label
tabling member	label

Search

1140582

	registered interest
	date	19/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	NHS: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, when he plans to issue guidance to health professionals on the Serious Shortage Protocol.
	tabling member constituency	North Norfolk
	tabling member printed	Norman Lamb
	uin	279389
	answer	answer is ministerial correction date of answer 26/07/2019 answer text <p>A Serious Shortage Protocol is an additional tool to manage serious medication shortages and may be used in the exceptional and rare situation when other measures have been exhausted or are likely to be ineffective.</p><p>At present we are currently working on the governance process for developing Serious Shortage Protocols, should one be required, through engagement, including with professional bodies and patient groups. Following this we will issue guidance to health professionals in due course.</p><p>The Pharmaceutical Services Negotiating Committee, the organisation who represent National Health Service community pharmacy contractors in England, have developed a briefing note to support community pharmacies, who will need to consider training and changes to their standard operating-procedures to take account of the potential new processes.</p><p>Any Serious Shortage Protocol would be developed by senior, specialist doctors and pharmacists, with input from national experts, Royal Colleges and specialist societies. If a Serious Shortage Protocol is to be authorised then there will also be engagement with the relevant patient groups, who can assist in informing patients. Pharmacists still have to use their professional judgment as to whether supplying against the protocol rather than the prescription is appropriate and provide the patient with relevant information. If they determine supply is not appropriate, then the patient should be referred back to their prescriber.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 26/07/2019 11:34:54 answering member 4455 label Biography information for Seema Kennedy previous answer version 131086 answering member constituency South Ribble answering member printed Seema Kennedy answering member 4455 label Biography information for Seema Kennedy
	tabling member	1439 label Biography information for Norman Lamb

1140584

	registered interest
	date	19/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	NHS: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what plans the Government has provide information to patients on changes to the provision of medicines as a result of the serious shortage protocol; and if he will make a statement.
	tabling member constituency	North Norfolk
	tabling member printed	Norman Lamb
	uin	279390
	answer	answer is ministerial correction date of answer 26/07/2019 answer text <p>A Serious Shortage Protocol is an additional tool to manage serious medication shortages and may be used in the exceptional and rare situation when other measures have been exhausted or are likely to be ineffective.</p><p>At present we are currently working on the governance process for developing Serious Shortage Protocols, should one be required, through engagement, including with professional bodies and patient groups. Following this we will issue guidance to health professionals in due course.</p><p>The Pharmaceutical Services Negotiating Committee, the organisation who represent National Health Service community pharmacy contractors in England, have developed a briefing note to support community pharmacies, who will need to consider training and changes to their standard operating-procedures to take account of the potential new processes.</p><p>Any Serious Shortage Protocol would be developed by senior, specialist doctors and pharmacists, with input from national experts, Royal Colleges and specialist societies. If a Serious Shortage Protocol is to be authorised then there will also be engagement with the relevant patient groups, who can assist in informing patients. Pharmacists still have to use their professional judgment as to whether supplying against the protocol rather than the prescription is appropriate and provide the patient with relevant information. If they determine supply is not appropriate, then the patient should be referred back to their prescriber.</p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 279391 question first answered 26/07/2019 11:36:12 answering member 4455 label Biography information for Seema Kennedy previous answer version 131087 answering member constituency South Ribble answering member printed Seema Kennedy answering member 4455 label Biography information for Seema Kennedy
	tabling member	1439 label Biography information for Norman Lamb

1140585

	registered interest
	date	19/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	NHS: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what discussions the Government has had with (a) patient groups and (b) professional bodies on the development of the serious shortage protocol.
	tabling member constituency	North Norfolk
	tabling member printed	Norman Lamb
	uin	279391
	answer	answer is ministerial correction date of answer 26/07/2019 answer text <p>A Serious Shortage Protocol is an additional tool to manage serious medication shortages and may be used in the exceptional and rare situation when other measures have been exhausted or are likely to be ineffective.</p><p>At present we are currently working on the governance process for developing Serious Shortage Protocols, should one be required, through engagement, including with professional bodies and patient groups. Following this we will issue guidance to health professionals in due course.</p><p>The Pharmaceutical Services Negotiating Committee, the organisation who represent National Health Service community pharmacy contractors in England, have developed a briefing note to support community pharmacies, who will need to consider training and changes to their standard operating-procedures to take account of the potential new processes.</p><p>Any Serious Shortage Protocol would be developed by senior, specialist doctors and pharmacists, with input from national experts, Royal Colleges and specialist societies. If a Serious Shortage Protocol is to be authorised then there will also be engagement with the relevant patient groups, who can assist in informing patients. Pharmacists still have to use their professional judgment as to whether supplying against the protocol rather than the prescription is appropriate and provide the patient with relevant information. If they determine supply is not appropriate, then the patient should be referred back to their prescriber.</p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 279390 question first answered 26/07/2019 11:36:13 answering member 4455 label Biography information for Seema Kennedy previous answer version 131085 answering member constituency South Ribble answering member printed Seema Kennedy answering member 4455 label Biography information for Seema Kennedy
	tabling member	1439 label Biography information for Norman Lamb

1143605

	registered interest
	date	02/09/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	HIV Infection: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps his Department is taking to (a) raise awareness of and (b) increase access to the PrEP impact trial in BAME communities.
	tabling member constituency	North Norfolk
	tabling member printed	Norman Lamb
	uin	285065
	answer	answer is ministerial correction date of answer 05/09/2019 answer text <p>A core function of the pre-exposure prophylaxis (PrEP) Impact Trial Community Advisory Board (CAB) is to raise awareness and uptake of PrEP in key populations including women and black, Asian and minority ethnic (BAME) communities. Further information about PrEP Impact Trial CAB activities and participating community groups can be found at the following links:</p><p><a href="https://www.england.nhs.uk/commissioning/spec-services/npc-crg/blood-and-infection-group-f/f03/prep-trial-updates/" target="_blank">https://www.england.nhs.uk/commissioning/spec-services/npc-crg/blood-and-infection-group-f/f03/prep-trial-updates/</a></p><p><a href="https://www.prepimpacttrial.org.uk/faqs" target="_blank">https://www.prepimpacttrial.org.uk/faqs</a></p><p>In addition, Public Health England’s Innovation Fund has supported a number of community based projects aimed at increasing PrEP awareness in women, BAME groups and trans communities; information on the projects funded in 2018 can be found at the following links:</p><p><a href="https://www.gov.uk/government/news/innovative-hiv-prevention-projects-reached-170000-people-in-2018" target="_blank">https://www.gov.uk/government/news/innovative-hiv-prevention-projects-reached-170000-people-in-2018</a></p><p>Since the start of the PrEP Impact Trial in October 2017, over half of the available 26,000 trial places have been filled. As of 3 September 2019, all participating Trial clinics were open to recruitment for women, trans men and heterosexual men. Information on the enrolment status of participating clinics is regularly updated on the PrEP Impact Trial website at the following link:</p><p><a href="https://www.prepimpacttrial.org.uk/join-the-trial" target="_blank">https://www.prepimpacttrial.org.uk/join-the-trial</a></p> answering member constituency Bury St Edmunds answering member printed Jo Churchill grouped question UIN 285069 question first answered 05/09/2019 15:28:31 answering member 4380 label Biography information for Jo Churchill
	tabling member	1439 label Biography information for Norman Lamb

1143606

	registered interest
	date	02/09/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	HIV Infection: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps his Department is taking to (a) raise awareness of and (b) increase access to the PrEP impact trial amongst women at high risk of contracting HIV.
	tabling member constituency	North Norfolk
	tabling member printed	Norman Lamb
	uin	285069
	answer	answer is ministerial correction date of answer 05/09/2019 answer text <p>A core function of the pre-exposure prophylaxis (PrEP) Impact Trial Community Advisory Board (CAB) is to raise awareness and uptake of PrEP in key populations including women and black, Asian and minority ethnic (BAME) communities. Further information about PrEP Impact Trial CAB activities and participating community groups can be found at the following links:</p><p><a href="https://www.england.nhs.uk/commissioning/spec-services/npc-crg/blood-and-infection-group-f/f03/prep-trial-updates/" target="_blank">https://www.england.nhs.uk/commissioning/spec-services/npc-crg/blood-and-infection-group-f/f03/prep-trial-updates/</a></p><p><a href="https://www.prepimpacttrial.org.uk/faqs" target="_blank">https://www.prepimpacttrial.org.uk/faqs</a></p><p>In addition, Public Health England’s Innovation Fund has supported a number of community based projects aimed at increasing PrEP awareness in women, BAME groups and trans communities; information on the projects funded in 2018 can be found at the following links:</p><p><a href="https://www.gov.uk/government/news/innovative-hiv-prevention-projects-reached-170000-people-in-2018" target="_blank">https://www.gov.uk/government/news/innovative-hiv-prevention-projects-reached-170000-people-in-2018</a></p><p>Since the start of the PrEP Impact Trial in October 2017, over half of the available 26,000 trial places have been filled. As of 3 September 2019, all participating Trial clinics were open to recruitment for women, trans men and heterosexual men. Information on the enrolment status of participating clinics is regularly updated on the PrEP Impact Trial website at the following link:</p><p><a href="https://www.prepimpacttrial.org.uk/join-the-trial" target="_blank">https://www.prepimpacttrial.org.uk/join-the-trial</a></p> answering member constituency Bury St Edmunds answering member printed Jo Churchill grouped question UIN 285065 question first answered 05/09/2019 15:28:31 answering member 4380 label Biography information for Jo Churchill
	tabling member	1439 label Biography information for Norman Lamb

964345

	registered interest
	date	03/09/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Self-harm: Children
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, how many (a) boys and (b) girls aged (i) 0-10, (ii) 11-13, (iii) 14, (iv) 15 and (v) 16 and 17 years old have been admitted to hospital in England as a result of (A) self-harm and (B) self-poisoning in each year since 2015.
	tabling member constituency	North Norfolk
	tabling member printed	Norman Lamb
	uin	169127
	answer	answer is ministerial correction date of answer 11/09/2018 answer text <p>A count of finished admission episodes (FAEs) with an external cause of self-harm and self-poisoning for boys and girls aged 0-10, 11-13, 14, 15 and 16 and 17 years old in England for the years 2014-15 to 2016-17 is shown in the attached table owing to its size.</p><p> </p><p>An FAE is the first period of admitted patient care under one consultant within one healthcare provider. FAEs are counted against the year or month in which the admission episode finishes. Admissions do not represent the number of patients, as a person may have more than one admission within the period.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price question first answered 11/09/2018 10:42:59 answering member 4065 label Biography information for Dame Jackie Doyle-Price attachment 1 file name PQ169127 format.xlsx title PQ169127 attached document
	tabling member	1439 label Biography information for Norman Lamb

1039003

	registered interest
	date	10/01/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Epilepsy: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether he plans to exclude epilepsy medications from the Serious Shortage Protocol for medicines; and if he will make a statement.
	tabling member constituency	North Norfolk
	tabling member printed	Norman Lamb
	uin	207181
	answer	answer is ministerial correction date of answer 15/01/2019 answer text <p>Any serious shortage protocol would be developed with and signed off by clinicians. Only if clinicians deem it appropriate, an alternative quantity, strength, pharmaceutical form or medicine can be dispensed in line with the protocol. Each protocol would clearly set out what action can be taken by the retail pharmacy, under what circumstances, for which patients and during which period.</p><p> </p><p>Protocols for therapeutic or generic equivalents will not be suitable for all medicines and patients. For example, they would not be suitable for treatments where the medicines that are prescribed need to be prescribed by brand for clinical reasons, for example anti-epilepsy medicines. In these cases, patients would always be referred back to the prescriber for any decision about their treatment before any therapeutic or generic alternative is supplied.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 15/01/2019 16:16:17 answering member 4067 label Biography information for Steve Brine
	tabling member	1439 label Biography information for Norman Lamb

1023254

	registered interest
	date	11/12/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Healthcare Environmental Services
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, pursuant to the Written Statement of 11 December 2018 on Clinical Waste, Official Report, HCWS1168, if he will publish the NHS trusts that continue to receive services from Healthcare Environmental Services.
	tabling member constituency	North Norfolk
	tabling member printed	Norman Lamb
	uin	201130
	answer	answer is ministerial correction date of answer 17/12/2018 answer text <p>As of 13 December, no National Health Service trusts with remaining contacts in place with Healthcare Environment Services are reporting that they are continuing to receive their scheduled clinical waste collections from Healthcare Environmental Services. Contingency arrangements are in place for each of the affected trusts. An optional extension in the Mitie contract has been exercised, which will allow all affected trusts to access a replacement clinical waste collection service, should they choose to do so.</p> answering member constituency Wimbledon answering member printed Stephen Hammond question first answered 17/12/2018 17:40:40 answering member 1585 label Biography information for Stephen Hammond
	tabling member	1439 label Biography information for Norman Lamb

923314

	registered interest
	date	13/06/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Pneumonia: Vaccination
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, how many stakeholders the Joint Committee on Vaccination and Immunisation has consulted on the revised schedule for the infant pneumococcal immunisation programme since its meeting of 7 February 2018.
	tabling member constituency	North Norfolk
	tabling member printed	Norman Lamb
	uin	153218
	answer	answer is ministerial correction date of answer 21/06/2018 answer text <p>As part of a stakeholder consultation on the childhood pneumococcal vaccination schedule, responses were sought from Pfizer, GlaxoSmithKline, Merck, Meningitis Now, and the Meningitis Research Foundation. Additional responses were received from the Confederation of Meningitis Organisations, the International Federation of Ageing, and the International Longevity Centre.</p><p> </p><p>The Joint Committee on Vaccination and Immunisation (JCVI) Pneumococcal sub-committee considered the responses received on 10 May 2018. The sub-committee reported to the JCVI on 6 June 2018. The minutes of these meetings will provide the Committee’s response to points raised during the consultation and will be published on or before 18 July 2018.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 153219 question first answered 21/06/2018 16:04:05 answering member 4067 label Biography information for Steve Brine
	tabling member	1439 label Biography information for Norman Lamb

923315

	registered interest
	date	13/06/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Pneumonia: Vaccination
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether the Joint Committee on Vaccination and Immunisation will respond to all stakeholder submissions on the proposal to reduce the number of doses in the infant pneumococcal vaccination programme.
	tabling member constituency	North Norfolk
	tabling member printed	Norman Lamb
	uin	153219
	answer	answer is ministerial correction date of answer 21/06/2018 answer text <p>As part of a stakeholder consultation on the childhood pneumococcal vaccination schedule, responses were sought from Pfizer, GlaxoSmithKline, Merck, Meningitis Now, and the Meningitis Research Foundation. Additional responses were received from the Confederation of Meningitis Organisations, the International Federation of Ageing, and the International Longevity Centre.</p><p> </p><p>The Joint Committee on Vaccination and Immunisation (JCVI) Pneumococcal sub-committee considered the responses received on 10 May 2018. The sub-committee reported to the JCVI on 6 June 2018. The minutes of these meetings will provide the Committee’s response to points raised during the consultation and will be published on or before 18 July 2018.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 153218 question first answered 21/06/2018 16:04:05 answering member 4067 label Biography information for Steve Brine
	tabling member	1439 label Biography information for Norman Lamb